HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $41.98 million. The enterprise value is $45.92 million.
| Market Cap | 41.98M |
| Enterprise Value | 45.92M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 37.82 million shares outstanding. The number of shares has increased by 3.73% in one year.
| Shares Outstanding | 37.82M |
| Shares Change (YoY) | +3.73% |
| Shares Change (QoQ) | +3.41% |
| Owned by Insiders (%) | 52.30% |
| Owned by Institutions (%) | 2.91% |
| Float | 17.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.11 |
| Forward PS | n/a |
| PB Ratio | 4.80 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 39.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.46, with a Debt / Equity ratio of 0.95.
| Current Ratio | 0.46 |
| Quick Ratio | 0.39 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -143.47 |
Financial Efficiency
Return on equity (ROE) is -146.80% and return on invested capital (ROIC) is -163.68%.
| Return on Equity (ROE) | -146.80% |
| Return on Assets (ROA) | -81.70% |
| Return on Capital (ROIC) | -163.68% |
| Revenue Per Employee | $25,835 |
| Profits Per Employee | -$608,703 |
| Employee Count | 45 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.63% in the last 52 weeks. The beta is 1.05, so HCW Biologics's price volatility has been similar to the market average.
| Beta (1Y) | 1.05 |
| 52-Week Price Change | -27.63% |
| 50-Day Moving Average | 1.50 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 29.08 |
| Average Volume (30 Days) | 20,014 |
Short Selling Information
The latest short interest is 8,623, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 8,623 |
| Short Previous Month | 7,627 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 1.17 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $1.16 million and -$27.39 million in losses. Loss per share was -$0.76.
| Revenue | 1.16M |
| Gross Profit | 1.16M |
| Operating Income | -27.85M |
| Pretax Income | -27.39M |
| Net Income | -27.39M |
| EBITDA | -26.12M |
| EBIT | -27.20M |
| Loss Per Share | -$0.76 |
Balance Sheet
The company has $4.33 million in cash and $8.27 million in debt, giving a net cash position of -$3.94 million or -$0.10 per share.
| Cash & Cash Equivalents | 4.33M |
| Total Debt | 8.27M |
| Net Cash | -3.94M |
| Net Cash Per Share | -$0.10 |
| Equity / Book Value | 8.74M |
| Book Value Per Share | 0.23 |
| Working Capital | -7.20M |
Cash Flow
In the last 12 months, operating cash flow was -$22.48 million and capital expenditures -$6.03 million, giving a free cash flow of -$28.51 million.
| Operating Cash Flow | -22.48M |
| Capital Expenditures | -6.03M |
| Free Cash Flow | -28.51M |
| FCF Per Share | -$0.77 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,395.57% and -2,356.12%.
| Gross Margin | 100.00% |
| Operating Margin | -2,395.57% |
| Pretax Margin | -2,356.12% |
| Profit Margin | -2,356.12% |
| EBITDA Margin | -2,246.95% |
| EBIT Margin | -2,339.81% |
| FCF Margin | -2,452.46% |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.73% |
| Shareholder Yield | -3.73% |
| Earnings Yield | -65.24% |
| FCF Yield | -67.91% |
Analyst Forecast
The average price target for HCW Biologics is $9.00, which is 718.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 718.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 211.26% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HCW Biologics has an Altman Z-Score of -5.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.62 |
| Piotroski F-Score | 2 |